Curative Biotechnology, Inc. (CUBT)
- Previous Close
0.0244 - Open
0.0225 - Bid --
- Ask --
- Day's Range
0.0225 - 0.0280 - 52 Week Range
0.0051 - 0.0400 - Volume
197,414 - Avg. Volume
214,394 - Market Cap (intraday)
16.326M - Beta (5Y Monthly) 224.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 23, 2024 - Apr 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the treatment of degenerative eye disease. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. The company was formerly known as Connectyx Technologies Holdings Group, Inc. and changed its name to Curative Biotechnology, Inc. in November 2020. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida.
curativebiotech.comRecent News: CUBT
Performance Overview: CUBT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CUBT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CUBT
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.39
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-179.94%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.02M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
636
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-192.69k
Company Insights: CUBT
CUBT does not have Company Insights